Akari Therapeutics Plc SEC filings AKTX

Akari Therapeutics Plc has 743 filings in SEC EDGAR's recent list, going back to Apr 13, 2012. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (shareholder vote results). The company's fiscal year ends on December 31.

Form Description Filed Period
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
10-Q Quarterly report May 19, 2026 Mar 31, 2026
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
10-Q Quarterly report Aug 13, 2025 Jun 30, 2025
10-Q Quarterly report May 14, 2025 Mar 31, 2025
10-Q Quarterly report Nov 19, 2024 Sep 30, 2024
10-Q Quarterly report Aug 19, 2024 Jun 30, 2024
10-Q Quarterly report May 15, 2024 Mar 31, 2024
10-Q Quarterly report May 12, 2016 Mar 31, 2016
10-Q Quarterly report Nov 23, 2015 Sep 30, 2015
10-Q Quarterly report Aug 12, 2015 Jun 30, 2015
10-Q Quarterly report May 12, 2015 Mar 31, 2015

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AKTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
Tampa, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1541157
Former names
Celsus Therapeutics Plc. (until Sep 15, 2015); Morria Biopharmaceuticals PLC (until Jun 20, 2013)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.